InstalabHHV-6 Panel
Should you take a HHV-6 Panel test?
This test is most useful if any of these apply to you.
2 Biomarkers Included
- HHV-6 IgGAn antibody your immune system produces after encountering human herpesvirus 6, a nearly universal childhood infection, indicating whether your body has been exposed to this virus.
- HHV-6 IgMAn early antibody your immune system produces when human herpesvirus 6 becomes active, signaling either a new infection or the virus waking up from dormancy.
About HHV-6 Panel
Almost every adult alive carries Human Herpesvirus 6 (HHV-6). Primary infection usually happens before age three, causing the classic childhood rash called roseola, and then the virus goes silent. It buries itself inside immune cells and stays dormant for decades. But "dormant" does not mean gone. Under the right conditions (stress, immune suppression, another illness), HHV-6 can wake back up, and a reactivation can look like anything from crushing fatigue to brain inflammation.
This panel measures two classes of antibodies your immune system makes against HHV-6. Together, they answer a question that neither test can answer alone: is the virus just a memory from childhood, or is it active right now? That distinction matters because reactivation has been linked to encephalitis (inflammation of the brain) in transplant recipients, and emerging evidence connects it to chronic fatigue, thyroid inflammation, and neurological symptoms in otherwise healthy people.
What This Panel Reveals
Your body produces different types of antibodies at different stages of an infection. Immunoglobulin M (IgM) antibodies are the first responders. They appear within days of an active infection or reactivation and typically fade within weeks to a few months. Immunoglobulin G (IgG) antibodies arrive later, build more slowly, and persist for life. They are the immune system's long-term memory of a past encounter.
Because roughly 90% to 95% of adults carry HHV-6 IgG antibodies, a positive IgG result alone tells you very little. It usually just confirms what population surveys already predict: you were infected as a child. The real value of the panel comes from reading the two results together. IgM status, combined with IgG levels, separates a decades-old resolved infection from one that may be active and contributing to symptoms right now.
How to Read Your Results Together
The clinical picture changes dramatically depending on which combination you see. The table below walks through the four possible patterns.
| HHV-6 IgG | HHV-6 IgM | What It Suggests |
|---|---|---|
| Positive | Negative | Past infection with no current activity. This is the most common adult result and is generally reassuring. |
| Positive | Positive | Likely reactivation. The virus has woken up and your immune system is actively fighting it. This pattern warrants follow-up, especially if you have unexplained fatigue, neurological symptoms, or a weakened immune system. |
| Negative | Positive | Possible very early primary infection, before IgG has had time to develop. Rare in adults. Retest in two to three weeks to confirm. |
| Negative | Negative | No evidence of past or current HHV-6 infection. Uncommon in adults given the virus's near-universal prevalence. |
A rising IgG level on repeat testing (drawn four to six weeks apart) adds another layer. A fourfold or greater increase in IgG between two draws is considered strong antibody-based evidence of reactivation, even if IgM is borderline. This is why serial testing matters for this panel.
Why Reactivation Matters
In transplant recipients and people with suppressed immune systems, HHV-6 reactivation is a recognized clinical event. Studies of bone marrow transplant patients have found that HHV-6 reactivation occurs in 30% to 70% of recipients, and it is the most common cause of viral brain inflammation in this population. The virus targets the brain's temporal lobes, the regions responsible for memory and language, causing confusion, memory loss, and seizures.
Outside of transplant medicine, the clinical picture is less settled but becoming clearer. A study of patients with chronic fatigue syndrome (CFS), now called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), found that 57.3% had evidence of active HHV-6 infection, detected through direct viral testing rather than antibody measurement, compared to 19.2% of healthy controls. Research has also identified associations between HHV-6 reactivation and Hashimoto's thyroiditis (autoimmune thyroid disease), with higher rates of active HHV-6 found in thyroid tissue from affected patients compared to controls. These findings come from direct virus detection methods, so this antibody panel serves as a screening step that can prompt more targeted testing.
HHV-6 has also drawn attention in multiple sclerosis (MS) research. A meta-analysis covering over 2,000 MS patients and controls found significantly higher HHV-6 antibody levels and viral detection rates in people with MS. The virus is not proven to cause MS, but the association is consistent enough that researchers continue to investigate it.
When Results Can Be Misleading
About 1% of the population carries chromosomally integrated HHV-6 (ciHHV-6), meaning the virus's genetic material has been permanently inserted into their own DNA and is passed from parent to child. These individuals can have persistently high antibody levels and even detectable viral DNA in their blood without any active infection. If your IgG is unexpectedly high and you have no symptoms, ciHHV-6 is worth considering and can be confirmed through specialized testing.
IgM results can also be tricky. Some tests cross-react with other herpesviruses, meaning the test mistakes antibodies made against a different virus for HHV-6 antibodies. This happens most often with cytomegalovirus (CMV) and Epstein-Barr virus (EBV). A positive IgM should always be interpreted alongside your symptoms and clinical context, not treated as a standalone diagnosis. False-positive IgM results can also occur when the immune system mounts a broad, nonspecific antibody response to any strong trigger.
Tracking Over Time
A single draw gives you a snapshot. Serial testing gives you a story. If you are investigating unexplained fatigue, neurological symptoms, or immune dysfunction, repeating this panel every four to six weeks lets you track whether IgG levels are rising (suggesting reactivation) or stable (suggesting a quiet, resolved infection). For people managing known HHV-6 reactivation, follow-up testing helps confirm whether antiviral treatment is working.
Annual testing makes sense for anyone with a history of reactivation, autoimmune thyroid disease, or immune suppression. Tracking antibody trends over time is far more informative than any single result in isolation.
What to Do with Your Results
If both results fit the most common pattern (IgG positive, IgM negative), no immediate action is needed. You carry the virus like most adults, and it is not currently active.
If IgM is positive or IgG levels are unusually high, the next step depends on your symptoms. For people with fatigue, cognitive difficulty, or neurological complaints, discuss the results with an infectious disease specialist or an immunologist. They may order HHV-6 DNA testing by PCR, a lab technique that detects the virus's genetic material directly in blood or spinal fluid, to confirm active viral replication. Antiviral medications have shown activity against HHV-6 in clinical settings, though treatment decisions depend heavily on the clinical picture.
Adding EBV and CMV antibody panels alongside this one is a practical next step if reactivation is suspected. These three herpesviruses share reactivation triggers and can co-reactivate, so testing all three together paints a more complete picture of your herpesvirus burden.